The litigation, spearheaded by the Rosen Law Firm, centers on allegations that GeneDx misled shareholders regarding the integration and viability of Fabric, an acquisition intended to optimize the company’s dry lab processes and reduce costs. According to the complaint, the company repeatedly touted potential efficiencies that allegedly failed to materialize, masking significant underlying operational problems that ultimately harmed investors when the reality surfaced.

While the lawsuit has been filed, no class has yet been certified. Investors who suffered losses during the specified period may participate in the litigation without out-of-pocket costs through a contingency fee arrangement. Participation as a lead plaintiff is optional; those who choose not to take an active role may remain absent class members, though they retain the right to select their own counsel or pursue the matter independently until a class is formally certified.